| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1e3005e73a875419e2b48c13c9533030
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f86553f8ce5baa9268ce5fd40e03595b |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-90
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-94 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2020-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_94ce40a743cf1faa2e088b750ac2e0c3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_df4cc407adbd4fcb4872817e2469aa3a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9bfadaa7a255bf8c6f2f35f728520609 |
| publicationDate |
2021-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2021093849-A1 |
| titleOfInvention |
A novel antibody against tigit |
| abstract |
The present invention provides TIGIT monoclonal antibodies, particularly humanized monoclonal antibodies specifically binding to TIGIT with high affinity. The present invention also provides functional monoclonal antibodies cross-reactive to TIGIT of human, cynomolgus monkey and mouse. The present invention further provides amino acid sequences of the antibodies of the invention, cloning or expression vectors, host cells and methods for expressing or isolating the antibodies. The epitopes of the antibodies are identified. Therapeutic compositions comprising the antibodies of the invention are also provided. The invention also provides methods for treating cancers and other diseases with anti-TIGIT antibodies. |
| priorityDate |
2019-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |